XBIT vs. RAPT, XERS, ELYM, CTMX, ENTA, INZY, NKTR, XOMA, VSTM, and CTNM
Should you be buying XBiotech stock or one of its competitors? The main competitors of XBiotech include RAPT Therapeutics (RAPT), Xeris Biopharma (XERS), Eliem Therapeutics (ELYM), CytomX Therapeutics (CTMX), Enanta Pharmaceuticals (ENTA), Inozyme Pharma (INZY), Nektar Therapeutics (NKTR), XOMA (XOMA), Verastem (VSTM), and Contineum Therapeutics (CTNM). These companies are all part of the "pharmaceutical preparations" industry.
XBiotech (NASDAQ:XBIT) and RAPT Therapeutics (NASDAQ:RAPT) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, dividends, community ranking, valuation, profitability, risk, earnings, institutional ownership and media sentiment.
RAPT Therapeutics has a consensus price target of $24.67, indicating a potential upside of 455.56%. Given RAPT Therapeutics' higher possible upside, analysts clearly believe RAPT Therapeutics is more favorable than XBiotech.
XBiotech's return on equity of -13.75% beat RAPT Therapeutics' return on equity.
XBiotech received 229 more outperform votes than RAPT Therapeutics when rated by MarketBeat users. Likewise, 69.98% of users gave XBiotech an outperform vote while only 66.67% of users gave RAPT Therapeutics an outperform vote.
XBiotech has higher revenue and earnings than RAPT Therapeutics. XBiotech is trading at a lower price-to-earnings ratio than RAPT Therapeutics, indicating that it is currently the more affordable of the two stocks.
55.7% of XBiotech shares are owned by institutional investors. Comparatively, 99.1% of RAPT Therapeutics shares are owned by institutional investors. 33.1% of XBiotech shares are owned by insiders. Comparatively, 6.6% of RAPT Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
XBiotech has a beta of 1.49, suggesting that its stock price is 49% more volatile than the S&P 500. Comparatively, RAPT Therapeutics has a beta of 0.52, suggesting that its stock price is 48% less volatile than the S&P 500.
In the previous week, RAPT Therapeutics had 15 more articles in the media than XBiotech. MarketBeat recorded 18 mentions for RAPT Therapeutics and 3 mentions for XBiotech. XBiotech's average media sentiment score of 1.62 beat RAPT Therapeutics' score of -0.29 indicating that XBiotech is being referred to more favorably in the media.
Summary
XBiotech beats RAPT Therapeutics on 10 of the 16 factors compared between the two stocks.
Get XBiotech News Delivered to You Automatically
Sign up to receive the latest news and ratings for XBIT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding XBIT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
XBiotech Competitors List
Related Companies and Tools
